BAX: Near-Term Headwinds Will Resolve As Margins Stabilize Into 2026

Key Takeaways

• Recovery in hospital activity and patient admissions is driving higher demand for Baxter's core products, supporting potential revenue and margin growth.
  
• Innovation and portfolio optimization, combined with new leadership, position Baxter for efficiency gains, higher-margin offerings, and long-term market share expansion.
  
• Volume recovery and profitability are at risk due to sustained demand weakness, supply chain issues, quality concerns, and margin pressures amid ongoing operational transitions.

Catalysts

Through its subsidiaries, provides a portfolio of healthcare products in the United States.

• Normalization of hospital purchasing patterns and patient admissions is expected to drive increased utilization of Baxter's core IV solutions and infusion systems as fluid conservation efforts abate, providing upside to revenue growth and margin expansion as volumes recover.
  
• Baxter's strengthened focus on innovation-including new product launches in advanced infusion systems, AI-enabled devices, and compounding-aligns with growing demand for efficient, digitalized, and connected healthcare equipment, positioning the company to capture higher-margin revenue streams and gain market share.
  
• An aging population and the rising prevalence of chronic diseases are long-term drivers of increased demand for Baxter's critical care, compounding, and advanced surgery products, supporting sustained top-line growth as these demographic shifts accelerate healthcare utilization.
  
• Ongoing portfolio optimization efforts, including divestitures, cost reductions, and a commitment to eliminate stranded costs by 2027, aim to streamline operations, improve efficiency, and drive net margin improvement, which should be reflected in future earnings growth.
  
• The appointment of a new CEO with a track record in operational excellence is expected to accelerate transformation initiatives, refocus the organization on innovation and commercial execution, and support long-term expansion in operating margins and EPS.

Baxter International Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Baxter International's revenue will grow by 2.8% annually over the next 3 years.
• Analysts assume that profit margins will increase from -8.4% today to 6.3% in 3 years time.
• Analysts expect earnings to reach $788.3 million (and earnings per share of $1.56) by about August 2029, up from -$968.0 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $1.4 billion in earnings, and the most bearish expecting $643.1 million.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 24.7x on those 2029 earnings, up from -14.3x today. This future PE is lower than the current PE for the US Medical Equipment industry at 26.2x.
• Analysts expect the number of shares outstanding to grow by 0.66% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 8.74%, as per the Simply Wall St company report.

Risks

• Ongoing hospital IV fluid conservation and a slower-than-anticipated return to historical usage patterns, with management now assuming 20% below-normal levels for the foreseeable future, pose a risk to volume recovery and may limit revenue growth if hospitals do not resume prior practices.
  
• Temporary suspension and quality-related field actions for Novum IQ infusion pumps-amid customer and regulatory scrutiny-raise the risk that the pause could extend or repeat, leading to lost momentum, delayed product launches, and potential market share loss, negatively impacting both revenue and operating margins.
  
• Sustained softness in U.S. injectables and inhaled anesthesia, compounded by unexpected shifts toward alternative administration routes (such as IV push), point to persistent demand weakness and potential product substitution or competitive threats, which could depress pharmaceutical segment sales and overall company revenues.
  
• Margin compression from unfavorable product mix, reduced manufacturing volumes, and ongoing absorption issues in the integrated supply chain have already resulted in lower-than-expected gross and operating margins, which could persist if volume/mix headwinds are not resolved promptly, thus impacting net margin and earnings growth.
  
• The ongoing need to manage and reduce stranded costs post-divestiture (such as the Kidney Care business) synchronized with the phase-out of lucrative TSA income introduces execution risk-if costs are not removed at the same pace as TSA roll-off, there could be a margin gap, further stressing net margins and overall profitability.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $28.73 for Baxter International based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $40.0, and the most bearish reporting a price target of just $23.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $12.4 billion, earnings will come to $788.3 million, and it would be trading on a PE ratio of 24.7x, assuming you use a discount rate of 8.7%.
• Given the current share price of $26.73, the analyst price target of $28.73 is 7.0% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.